NasdaqGM:IRONBiotechs
Disc Medicine (IRON) Stock Could Be 64% Below Fair Value After EHA Trial Update
Disc Medicine (IRON) stock is in focus after the company reported updated clinical data at the EHA Annual Meeting in Stockholm, highlighting results from its RALLY MF and HELIOS trials in hematologic disorders.
See our latest analysis for Disc Medicine.
At a share price of $69.83, Disc Medicine has seen a 90 day share price return of 18.02%, while the year to date share price return is down 11.71% and the 1 year total shareholder return is 39.41%.
If fresh trial data has your attention, this...